• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
73,134.32 1,186.77
( 1.65%)
Global Indices
Nasdaq
46,363.90 1,126.75
(2.49%)
Dow Jones
6,550.24 185.52
(2.91%)
Hang Seng
53,589.67 2,525.95
(4.95%)
Nikkei 225
10,176.45 48.49
(0.48%)
Forex
USD-INR
94.31 -0.22
(-0.23%)
EUR-INR
108.30 -0.48
(-0.44%)
GBP-INR
124.69 -0.63
(-0.50%)
JPY-INR
0.59 0.00
(0.19%)

EQUITY - MARKET SCREENER

Algoquant Fintech Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
505725
INE598D01035
4.0092314
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ALGOQUANT
78.17
1406.32
EPS(TTM)
Face Value()
Div & Yield %
0.64
1
0
 

&hra pradesh state financial corpn ltd
Dr Reddy’s Swiss subsidiary gets USFDA CRL for biosimilar AVT03
Jan 01,2026
AVT03 is a proposed biosimilar to Amgen’s Prolia and Xgeva and has been developed by Alvotech hf. According to the company, the CRL pertains to observations made by the US Food and Drug Administration (USFDA) during a pre-licence inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland.

Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company’s consolidated net profit jumped 7.3% to Rs 1,347.10 crore on a 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

The counter slipped 1.66% to Rs 1,250 on the BSE.